A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-RANGING STUDY TO COMPARE THE SAFETY AND EFFICACY OF 3 DOSE LEVELS OF AV-1 IN HEALTHY ADULTS CHALLENGED WITH A CONTROLLED HUMAN INFECTION S

NIH RePORTER · NIH · N01 · $321,765 · view on reporter.nih.gov ↗

Abstract

To support a phase two clinical trial to evaluate a dengue vaccine candidate.

Key facts

NIH application ID
11076168
Project number
75N93019D00031-P00001-759302300004-1
Recipient
JOHNS HOPKINS UNIVERSITY
Principal Investigator
Anna Palmer Durbin
Activity code
N01
Funding institute
NIH
Fiscal year
2024
Award amount
$321,765
Award type
—
Project period
2023-08-23 → 2025-07-22